Background: During the COVID-19 pandemic, physical and mental health of the nurses is greatly challenged since they work under unprecedented pressure and they are more vulnerable to the harmful effects of the disease. Aim: To examine the impact of the COVID-19 pandemic on nurses9 burnout and to identify associated risk factors. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for this systematic review and meta-analysis. PubMed, Scopus, ProQuest, and pre-print services (medRxiv and PsyArXiv) were searched from January 1, 2020 to November 15, 2020 and we removed duplicates. We applied a random effect model to estimate pooled effects since the heterogeneity between results was very high. Findings: Fourteen studies, including 17,390 nurses met the inclusion criteria. Five standardized and valid questionnaires were used to measure burnout among nurses; Maslach Burnout Inventory, Copenhagen Burnout Inventory, Professional Quality of Life Scale version 5, Mini-Z, and Spanish Burnout Inventory. The overall prevalence of emotional exhaustion was 34.1% (95% confidence interval [CI]: 22.5-46.6%), of depersonalization was 12.6% (95% CI: 6.9-19.7%), and of lack of personal accomplishment was 15.2% (95% CI: 1.4-39.8%). The following factors were associated with increased nurses9 burnout: younger age, higher educational level, higher degree, decreased social support, having a relative/friend diagnosed with COVID-19, low family and colleagues readiness to cope with COVID-19 outbreak, increased perceived threat of Covid-19, longer working time in quarantine areas, working in a high-risk environment (a COVID-19 designated hospital, a COVID-19 unit, etc.), working in hospitals with inadequate and insufficient material and human resources, decreased working safety while caring for COVID-19 patients, increased workload, decreased self-confidence in self-protection, and lower levels of specialized training regarding COVID-19, job experience, and self-confidence in caring for COVID-19. Conclusion: Nurses experience high levels of burnout during the COVID-19 pandemic, while several sociodemographic, social, and occupational factors affect this burnout. Several interventions need to be implemented to mitigate mental health impact of the COVID-19 pandemic on nurses, e.g. screening for mental health illness and early supportive interventions for high-risk nurses, immediate access to mental health care services, social support to reduce feelings of isolation, sufficient personal protective equipment for all nurses to provide security, etc. Governments, health care organizations, and policy makers should act in this direction to prepare health care systems, individuals, and nurses for a better response against the COVID-19 pandemic.
Aim: To determine whether healthcare workers (HCW) hospitalized in Spain due to COVID-19 have a worse prognosis than non-healthcare workers (NHCW). Methods: Observational cohort study based on the SEMI-COVID-19 Registry, a nationwide registry that collects sociodemographic, clinical, laboratory, and treatment data on patients hospitalised with COVID-19 in Spain. Patients aged 20-65 years were selected. A multivariate logistic regression model was performed to identify factors associated with mortality. Results: As of 22 May 2020, 4393 patients were included, of whom 419 (9.5%) were HCW. Median (interquartile range) age of HCW was 52 (15) years and 62.4% were women. Prevalence of comorbidities and severe radiological findings upon admission were less frequent in HCW. There were no difference in need of respiratory support and admission to intensive care unit, but occurrence of sepsis and in-hospital mortality was lower in HCW (1.7% vs. 3.9%; p=0.024 and 0.7% vs. 4.8%; p<0.001 respectively). Age, male sex and comorbidity, were independently associated with higher in-hospital mortality and healthcare working with lower mortality (OR 0.219, 95%CI 0.069-0.693, p=0.01). 30-days survival was higher in HCW (0.968 vs. 0.851 p<0.001). Conclusions: Hospitalized COVID-19 HCW had fewer comorbidities and a better prognosis than NHCW. Our results suggest that professional exposure to COVID-19 in HCW does not carry more clinical severity nor mortality.
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia - Condition: COVID-19
Intervention: Drug: Nafamostat Mesilate
Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults - Condition: COVID-19
Interventions: Drug: AZD7442; Drug: Placebo
Sponsors: AstraZeneca; QuintilesIMS
Not yet recruiting
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. - Condition: COVID-19
Interventions: Drug: AZD7442; Drug: Placebo
Sponsors: AstraZeneca; QuintilesIMS
Not yet recruiting
Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia - Condition: Covid19
Intervention: Dietary Supplement: Rhea Health Tone®
Sponsors: Universitas Padjadjaran; PT. Rhea Pharmaceutical Sciences Indonesia; Prodia Diacro Laboratories P.T.
Not yet recruiting
Fase I Clinical Trial on NK Cells for COVID-19 - Conditions: Covid19; Sars-cov 2
Intervention: Biological: Natural Killer Cells infusion
Sponsor: Hospital de Clinicas de Porto Alegre
Not yet recruiting
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) - Condition: COVID-19
Interventions: Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: Low-dose placebo (18-59 years) & Two dose regimen; Biological: Low-dose placebo (18-59 years) & Three dose regimen; Biological: High-dose placebo (18-59 years) & Two dose regimen; Biological: High-dose placebo (18-59 years) & Three dose regimen; Biological: Low-dose placebo (60-85 years) & Two dose regimen; Biological: Low-dose placebo (60-85 years) & Three dose regimen; Biological: High-dose placebo (60-85 years) & Two dose regimen; Biological: High-dose placebo (60-85 years) & Three dose regimen
Sponsors: Jiangsu Province Centers for Disease Control and Prevention; West China Hospital
Recruiting
Hydrogen Therapy in Patients With Moderate Covid-19 - Condition: Covid-19
Intervention: Drug: Mixture 3,6% H2 in N2 (96.4%)
Sponsor: University Hospital, Grenoble
Not yet recruiting
Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID) - Condition: Covid19
Intervention: Drug: Chloroquine
Sponsor: Fundacion Clinica Valle del Lili
Active, not recruiting
Adaptive COVID-19 Treatment Trial 4 (ACTT-4) - Condition: COVID-19
Interventions: Drug: Baricitinib; Drug: Dexamethasone; Other: Placebo; Drug: Remdesivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India - Condition: COVID-19
Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol); Dietary Supplement: Zinc (zinc gluconate); Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol); Other: Placebo
Sponsors: Harvard School of Public Health; Foundation for Medical Research; University Health Network, Toronto
Not yet recruiting
Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID) - Condition: Covid19
Interventions: Other: Respiratory rehabilitation program (RR).; Other: Respiratory tele-rehabilitation program (TRR).
Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Not yet recruiting
Inhaled Heparin for Hospitalised COVID-19 Patients - Condition: Covid19
Intervention: Drug: Unfractionated heparin
Sponsors: Australian National University; Helwan University; Clinica San Camilo, Argentina
Recruiting
Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection - Condition: Covid19
Interventions: Drug: Cholecalciferol; Other: Placebo
Sponsors: University of Liege; Laboratoires SMB S.A.
Recruiting
Efficacy and Safety of Ovotransferrin in COVID-19 Patients - Condition: Covid19
Intervention: Dietary Supplement: Ovotransferrin
Sponsor: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Not yet recruiting
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 - Condition: Covid19
Interventions: Drug: TM5614; Other: Placebo
Sponsor: Northwestern University
Recruiting
Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe - CONCLUSIONS: The results seem to confirm an association between BCG-positive vaccination policy and salmiak consumption, and lower death rates from COVID-19. Implementing BCG vaccination policy and fortification of foods with salmiak (NH4Cl) may have a significant impact on the control of SARS-CoV epidemic.
Dysregulated immunity in SARS-CoV-2 infected pregnant women - CONCLUSIONS AND RELEVANCE: SARS-CoV-2 infection during pregnancy was characterized by placental inflammation and reduced antiviral antibody responses, which may impact the efficacy of COVID-19 therapeutics in pregnancy. The long-term implications of placental inflammation for neonatal health also requires greater consideration.
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics - Hyperinflammation and lymphopenia provoked by SARS-CoV-2-activated macrophages contribute to the high mortality of Coronavirus Disease 2019 (COVID-19) patients. Thus, defining host pathways aberrantly activated in patient macrophages is critical for developing effective therapeutics. We discovered that G9a, a histone methyltransferase that is overexpressed in COVID-19 patients with high viral load, activates translation of specific genes that induce hyperinflammation and impairment of T cell…
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2 - Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a novel series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of SARS-CoV-2 spike protein, blocking out viral receptor ACE2. The lead drug possessing an Fc tag ( Nanosota-1C-Fc ) bound to SARS-CoV-2 RBD with a K (d) of 15.7picomolar (∼3000 times more tightly…
One novel virus, different beliefs as playmakers towards disease spread in Africa: looking at COVID-19 from a religious lens - Religious and spiritual observances that draw large people together are pervasive in many parts of the world, including Africa. With the recent emergence of COVID-19, these mass religious gatherings may pose significant threats to human health. Given the compromised healthcare systems in many parts of Africa, faith-based institutions have a huge responsibility towards the management of the potential spread of the virus through effective organizational strategies or interventions. This essay…
Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection - SARS-CoV-2 is a highly contagious virus and is causing a global pandemic. SARS-CoV-2 infection depends on the recognition of and binding to the cellular receptor human angiotensin-converting enzyme 2 (hACE2) through the receptor-binding domain (RBD) of the spike protein, and disruption of this process can effectively inhibit SARS-CoV-2 invasion. Plasma-activated water efficiently inactivates bacteria and bacteriophages by causing damage to biological macromolecules, but its effect on coronavirus…
Inhibiting the reproduction of SARS-CoV-2 through perturbations in human lung cell metabolic network - Viruses rely on their host for reproduction. Here, we made use of genomic and structural information to create a biomass function capturing the amino and nucleic acid requirements of SARS-CoV-2. Incorporating this biomass function into a stoichiometric metabolic model of the human lung cell and applying metabolic flux balance analysis, we identified host-based metabolic perturbations inhibiting SARS-CoV-2 reproduction. Our results highlight reactions in the central metabolism, as well as amino…
Structure of nonstructural protein 1 from SARS-CoV-2 - The periodic emergence of novel coronaviruses (CoVs) represents an ongoing public health concern with significant health and financial burden worldwide. The most recent occurrence originated in the city of Wuhan, China where a novel coronavirus (SARS-CoV-2) emerged causing severe respiratory illness and pneumonia. The continual emergence of novel coronaviruses underscores the importance of developing effective vaccines as well as novel therapeutic options that target either viral functions or…
Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis - Transcription of SARS-CoV-2 mRNA requires sequential reactions facilitated by the replication and transcription complex (RTC). Here, we present a structural snapshot of SARS-CoV-2 RTC as it transitions toward cap structure synthesis. We determine the atomic cryo-EM structure of an extended RTC assembled by nsp7-nsp8(2)-nsp12-nsp13(2)-RNA and a single RNA-binding protein, nsp9. Nsp9 binds tightly to nsp12 (RdRp) NiRAN, allowing nsp9 N terminus inserting into the catalytic center of nsp12 NiRAN,…
Metformin Is Associated With Decreased 30-Day Mortality Among Nursing Home Residents Infected With SARS-CoV2 - CONCLUSIONS AND IMPLICATIONS: Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens. These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects. A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19.
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 In Vitro - At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped positive-sense RNA virus, was identified for the first time in Wuhan, a city in the Chinese province of Hubei, as the cause of a new pathology which was later named coronavirus disease of 2019 (COVID-19).¹ SARS-CoV2 belongs to the family Coronaviridae and shares 79% nucleotide sequence identity with SARS-CoV and 96% with bat-coronavirus RatG13.^(1,2) The most frequent symptoms of COVID-19 are cough,…
Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach - Down syndrome (DS) is the most common genetic cause of learning difficulties and intellectual disabilities. DS patients often present with several congenital defects and chronic diseases, including immunity disorders. Elevated levels of pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) have been seen, which appear to vary with age. At birth, patients present with combined immunodeficiency, with frequent infections that decrease with age. Furthermore,…
The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor - The effect of the polyanionic polymer of inorganic polyphosphate (polyP) involved in innate immunity on the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to the cellular ACE2 receptor was studied. The RBD surface comprises a basic amino acid stretch of four arginine residues which interact with the physiological polyP (polyP(40)) and polyP(3). Subsequently, the interaction of RBD with ACE2 is sensitively inhibited. After the chemical modification of arginine, an…
Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking studies unveils an opportunity against CORONA - CONCLUSION: Compounds have a great potential to become COVID-19 main protease Mpro inhibitor. Nevertheless for their medicinal use further investigation is necessary.
Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions - The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular…
AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19 -
SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법 - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.
Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten -
Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.
wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Atemschutz-Baukastensystem, das aufweist:
Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.
제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .
JPEG
112020094463686-pat00017.jpg
48
135
新型冠状病毒中和性抗体滴度检测ELISA试剂盒 - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒,其中包括:包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低,操作简单,高灵敏度、高特异性、高准确度的特点,可用于新型冠状病毒中和抗体的批量、快速检测。
Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion -
Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.
Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.